trial · primary record
Ruxolitinib
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 70 |
| Primary completion | 2027-12-01 |
| Primary endpoint | Response defined as a 30% improvement from baseline in the Severity of Alopecia Tool (SALT) score at 32 weeks. |
| Registry ID | NCT05398809 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:45.400Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05398809
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ruxolitinib · approval
- Ruxolitinib · compound